DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Radioactive Iodide (131I) Treatment of 124I PET/CT Detected Breast Cancers

Information source: Stanford University
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Breast Cancer; Metastatic Breast Cancer

Intervention: 124 PET/CT imaging (Procedure); Na134I (Drug); Tri-iodothyronine (Drug); Tri-iodothyronine (Drug)

Phase: N/A

Status: Withdrawn

Sponsored by: Stanford University

Official(s) and/or principal investigator(s):
Irene L. Wapnir, Principal Investigator, Affiliation: Stanford University

Summary

This is a treatment protocol designed to accompany the ongoing institutional 124I PET/CT pilot imaging study for patients with invasive breast cancer. Women whose tumors express NIS [Na+I- symporter, sodium iodide symporter] and demonstrate radioiodide uptake on 124I PET/CT scans will be eligible for 131I treatment if, (1) tumor dosimetry calculations yield a cumulative radiation dose of at least 30Gy in target tumor, (2) estimated cumulative thyroid irradiation is less than 500 cGy and, (3) the therapeutic dose of 131I is in the range of 25 to 100 mCi.

Clinical Details

Official title: Radioactive Iodide (131I) Treatment of 124I PET/CT Detected Breast Cancers

Study design: Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: Target lesion size will be assessed clinically or radiologically in two directions . RECIST (Response Evaluation Criteria In Solid Tumors) will be implemented to determine response

Secondary outcome: Non target lesion size will be assessed clinically or radiologically in two directions . RECIST (Response Evaluation Criteria In Solid Tumors) will be implemented to determine response

Eligibility

Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Patients with measurable locally advanced or metastatic breast cancer who completed

124I PET/CT imaging study.

- Patients who are 18 years of age or older.

- Patients must have a life expectancy of at least 3 months.

- I 124 dosimetry completed with thyroid dose to 500 cGy or less and tumor dose of 2500

cGy or more.

- I131 therapeutic dose calculated from dosimetry. Dose must be in a range of 25 to 150

mCi.

- Patients with Eastern Cooperative Oncology Group (ECOG) Performance Status 0-3 will

be eligible.

- Use of concurrent systemic therapy (hormonal or cytotoxic) if associated with stable

disease for at least three months prior to treatment.

- Women with locally advanced breast cancer and simultaneous metastases, even if

surgery to eradicate local disease has taken place.

- Thyroid stimulating hormone (TSH) must be < 0. 4 uIU/mL.

- White blood cell count >= 1,500 and platelet count >= 40,000

- Women receiving thyroid hormone supplements and methimazole.

- Ability to understand and the willingness to sign a written informed consent

document.

- Premenopausal women must use contraception while receiving this treatment and during

follow-up period of 42 days. Exclusion Criteria:

- Stage 0-II breast cancer.

- Pregnant or nursing women.

- Not able to sign informed consent.

- Untreated psychiatric disorder.

- Women who have not had I124 PET/CT scan and dosimetry calculations.

- Radioiodide uptake in non-target organs or bone marrow does not exceed 25 cGy by

pre-treatment dosimetry.

- Received chemotherapy less than 4 weeks before.

- History of thyroid cancer.

Locations and Contacts

Stanford University School of Medicine, Stanford, California 94305, United States
Additional Information

Starting date: July 2010
Last updated: April 22, 2013

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017